Hyperuricemia as a Mediator of the Proinflammatory Endocrine Imbalance in the Adipose Tissue in a Murine Model of the Metabolic Syndrome by Baldwin, William et al.
Hyperuricemia as a Mediator of the Proinﬂammatory
Endocrine Imbalance in the Adipose Tissue in a Murine
Model of the Metabolic Syndrome
William Baldwin,
1 Steven McRae,
1 George Marek,
1 David Wymer,
1 Varinderpal Pannu,
1 Chris Baylis,
2
Richard J. Johnson,
1,3 and Yuri Y. Sautin
1
OBJECTIVE—Hyperuricemia is strongly associated with obe-
sity and metabolic syndrome and can predict visceral obesity and
insulin resistance. Previously, we showed that soluble uric acid
directly stimulated the redox-dependent proinﬂammatory signal-
ing in adipocytes. In this study we demonstrate the role of
hyperuricemia in the production of key adipokines.
RESEARCH DESIGN AND METHODS—We used mouse 3T3-
L1 adipocytes, human primary adipocytes, and a mouse model of
metabolic syndrome and hyperuricemia.
RESULTS—Uric acid induced in vitro an increase in the pro-
duction (mRNA and secreted protein) of monocyte chemotactic
protein-1 (MCP-1), an adipokine playing an essential role in induc-
ing the proinﬂammatory state in adipocytes in obesity. In addition,
uric acid caused a decrease in the production of adiponectin, an
adipocyte-speciﬁc insulin sensitizer and anti-inﬂammatory agent.
Uric acid–induced increase in MCP-1 production was blocked by
scavenging superoxide or by inhibiting NADPH oxidase and by
stimulating peroxisome-proliferator–activated receptor-g with rosi-
glitazone. Downregulation of the adiponectin production was pre-
vented by rosiglitazone but not by antioxidants. In obese mice with
metabolic syndrome, we observed hyperuricemia. Lowering uric
acid in these mice by inhibiting xanthine oxidoreductase with al-
lopurinol could improve the proinﬂammatory endocrine imbalance
in the adipose tissue by reducing production of MCP-1 and increas-
ing production of adiponectin. In addition, lowering uric acid in
obese mice decreased macrophage inﬁltration in the adipose tissue
and reduced insulin resistance.
CONCLUSIONS—Hyperuricemia might be partially responsible
for the proinﬂammatory endocrine imbalance in the adipose
tissue, which is an underlying mechanism of the low-grade in-
ﬂammation and insulin resistance in subjects with the metabolic
syndrome. Diabetes 60:1258–1269, 2011
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levated blood levels of uric acid, the ﬁnal product
of the purine degradation in humans, is strongly
associated with cardiovascular and kidney dis-
ease, hypertension, and overall risk of mortality
(1,2). It is also commonly present in metabolic syndrome
(3). Serum levels of uric acid are positively correlated with
individual components of the metabolic syndrome, in
particular visceral obesity (4,5), and this correlation is
stronger when other components are also present (5). In
1993 Reaven and colleagues (6) suggested that hyperuri-
cemia is commonly part of the cluster of metabolic and
hemodynamic abnormalities along with abdominal obe-
sity, glucose intolerance, insulin resistance, dyslipidemia,
and hypertension (7). Most authorities have viewed the
presence of hyperuricemia in metabolic syndrome as
a secondary response to obesity and hyperinsulinemia and
have attributed this to the effects of insulin on proximal
tubular urate transport (8), the effect of elevated leptin (9),
or altered purine metabolism (10).
Recent studies, however, have suggested a potential
contributory role of uric acid to metabolic syndrome. For
example, an elevated serum uric acid has been reported to
be an independent predictor of obesity (11) and hyper-
insulinemia (12,13), and thus if it precedes the de-
velopment of hyperinsulinemia, it is difﬁcult to attribute it
solely to the effects of elevated insulin levels. Lowering
uric acid also ameliorates the elevation in blood pressure,
serum triglycerides, and insulin resistance in the fructose-
induced metabolic syndrome in rats (3,14). We showed
recently that adipocyte differentiation is associated with
an increase in uptake of uric acid by cells and, in dif-
ferentiated adipocytes, uric acid induced an activation
of NADPH oxidase (NOX) followed by the activation of
redox-dependent proinﬂammatory signaling via protein
kinase p38 (15).
Adipose tissue is important not only as a site for fat
sequestration and storage, but also as a major endocrine
gland that secretes hormones and cytokines referred to as
adipokines (16,17). Adipocytes from lean and healthy
subjects express high levels of adiponectin, which is se-
creted into the circulation, reaching serum concentrations
of up to 10 mg/mL (18,19). Adiponectin stimulates fat oxi-
dation, acts as an insulin sensitizer in many cell types
(19,20), and has antiatherogenic properties (21). In obese
subjects, adiponectin levels are decreased, and its ben-
eﬁcial effects are diminished (20,22,23). Obesity is also
associated with an inﬂammatory response in the adipose
tissue (24,25) with an increased local expression of
monocyte chemotactic protein-1 (MCP-1), tumor necrosis
factor-a (TNF-a), interleukin-6 (IL-6), and other proin-
ﬂammatory molecules (23,25,26). MCP-1 has a key role in
the macrophage inﬁltration in the adipose tissue in obesity
and development of insulin resistance (27,28). The obesity-
induced imbalance in the production of adipokines con-
tributes to insulin resistance of the liver and muscles,
impairs vascular homeostasis, and induces low-grade sys-
temic inﬂammation that is critical in the development of
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ORIGINAL ARTICLEtype 2 diabetes and cardiovascular disease (18,19,29,30).
Uric acid has also been reported to induce an increase in
the expression of MCP-1 in some cell types (31,32) while
clinical studies revealed a negative correlation between
the levels of uric acid and adiponectin in the serum (33–
35). In addition, uric acid is recognized by immune cells
as a signal of cell death that alerts the immune system
(36,37). Recently Cheung et al. (38) have reported that the
xanthine dehydrogenase form of xanthine oxidoreductase
(XOR), the enzyme that produces uric acid from xanthine,
may also have a role in adipocyte differentiation.
Given these observations, we investigated whether uric
acid might modulate the production of adiponectin and MCP-
1 in the adipocyte and if this was dependent on local oxi-
dative stress or peroxisome-proliferator–activated receptor-g
(PPAR-g). We also examined whether hyperuricemia can
be a factor contributing to the proinﬂammatory imbalance
in the adipose tissue via effects on the MCP-1 and adipo-
nectin production in a mouse model of the metabolic syn-
drome.
RESEARCH DESIGN AND METHODS
Cell culture and treatments. Mouse preadipocyte cells 3T3-L1 obtained from
ATCC (Manassas, VA) were maintained in high glucose Dulbecco’s modiﬁed
Eagle’s medium (Invitrogen, Carlsbad, CA) supplemented with 10% FBS
and antibiotics. For adipocyte differentiation, conﬂuent cells were treated with
10 mg/mL insulin, 0.25 mmol/L dexamethasone, and 0.5 mmol/L isobutyl-1-
methylxanhine for 2 days followed by 3- to 5-day treatment with insulin alone.
Differentiation of adipocytes was conﬁrmed by lipid staining with Red Oil and
mRNA expression of PPAR-g and adiponectin as described earlier (15). Hu-
man primary subcutaneous adipocytes were obtained from ZenBio (Research
Triangle Park, NC) and cultured following the instruction of the manufacturer
in subcutaneous adipocyte medium AM-1 (ZenBio). Uric acid solution for cell
treatments (Ultrapure, 1–15 mg/dL; Sigma) was prepared in prewarmed cell
culture medium as previously described (15). If treatments with uric acid were
continued for more than 3 days, medium was replaced with freshly prepared
identical medium. By the end of the 3-day treatment, there was no difference
in pH between cell culture medium containing uric acid and control medium.
In some experiments, conditioned medium was collected and stored at 280°C
for measuring the levels of adipokines.
Animal model. The Animal Care and Use Committee of the University of
Florida approved protocols for all animal experiments. To test the effect of
lowering uric acid, we used the Pound mouse, a recently established pre-
diabetes/metabolic syndrome model (Charles River, Wilmington, MA). These
mice have a mutation in the leptin receptor (a deletion of the exon 2), and
they develop obesity, insulin resistance, dyslipidemia, and fatty liver disease
but do not progress to type 2 diabetes (39). In preliminary experiments we
showed that these mice develop hyperuricemia (RESULTS). Obese (C57BL/
6NCrl-Lepr
db-lb/Crl) and lean (C57BL/6NCrl) 6-week-old mice were maintained
on a standard Purina 5001 Diet (PMI, Richmond, IN) under a 12-h light/12-h
dark cycle with access to food and water ad libitum. To assess the effects of
lowering uric acid levels, obese and lean animals (8–10 animals per group)
were either administered for 8 weeks with allopurinol, an inhibitor of XOR
(125 mg/L in the drinking water; Sigma, St. Louis, MO) or remained untreated.
Every 3 weeks, samples of blood were obtained through facial vein to monitor
the level of uric acid. Insulin tolerance testing was performed 1 week prior to
the end of the experiment. Animals were fasted for 4 h and then injected in-
traperitoneally with insulin (Humulin R; Eli Lilly, Indianapolis, IN) at 1 unit/kg
body wt. Glucose in tail vein blood was measured immediately before in-
jection (time 0) and at 15, 30, 60, 90, and 120 min after injection using One-
Touch Ultra glucometer (LifeScan, Milpitas, CA). At the end of the treatment
period, the animals were killed by the intraperitoneal injection of 150 mg/kg
sodium pentobarbital. Blood was collected via cardiac puncture, and serum
was stored in aliquots at 280°C. For the mean arterial blood pressure (MAP)
measurements, animals were placed under anesthesia (1–3% isoﬂurane), and
arterial blood pressure was measured via the carotid artery by inserting a
27-gauge needle connected to a pressure transducer as described (40,41)
followed by blood collection. While measurement of blood pressure under
anesthesia may not recapitulate values in the conscious, unstressed state, we
have previously reported that differences in MAP between experimental
groups are maintained (40). Samples of visceral adipose tissue were col-
lected on ice and rinsed in ice-cold PBS. For RNA isolation, tissue samples
were preserved in RNAlater Solution (Applied Biosystems/Ambion, Austin, TX)
at 280°C.
Quantitative real-time RT-PCR. Total RNA was extracted using TRIzol re-
agent (Invitrogen, Carlsbad, CA). Trace DNA was removed using a DNA-free kit
(Applied Biosystems/Ambion, Austin, TX), and 0.5 mg of total RNA was con-
verted to cDNA using iScript cDNA synthesis kit (Bio-Rad, Hercules, CA).
Quantitative real-time RT-PCR was performed using SsoFast EvaGreen
Supermix (Bio-Rad) with primers spanning two or more exons and optimized
for real-time PCR, which were designed using Geneious Pro software (v. 4.8;
Biomatters Ltd., Auckland, New Zealand) and Beacon Designer (v. 7.70; Pre-
mier Biosoft International, Palo Alto, CA). Sequences for all used primers are
shown in Table 1. Real-time PCR was performed using CFX96 real-time PCR
detection system as follows: 50°C for 2 min, then 95°C for 2 min, then 40 cycles
of denaturation at 95°C for 15 s, annealing at 55°C for 30 s, and extension at
72°C for 30 s. Reaction speciﬁcity was conﬁrmed by 1) electrophoresis of
products in 2% agarose gel after real-time RT-PCR to check if bands of
expected size were detected; 2) melting curve analysis; and 3) sequencing
ampliﬁed fragments. Relative gene expression was analyzed by DDC(t)
method using the CFX Manager software (v. 1.6; Bio-Rad, Hercules, CA).
Immunohistochemistry. To assess the macrophage inﬁltration in the adipose
tissue, samples of the visceral adipose tissue were collected in 10% buffered
formalin, processed, embedded in parafﬁn, and sectioned. Macrophages were
stained as described (42) with the F4/80 antibody from Invitrogen/Caltag
Laboratories (Carlsbad, CA), secondary horseradish peroxidase–conjugated
antibody, diaminobenzidine chromogen, and a hematoxylin counterstain.
Measurement of serum levels of MCP-1 and adiponectin. Levels of MCP-1
and adiponectin in the cell culture medium were measured using the multiplex
mouse adipocyte LINCOplex kit (Linco Research, St. Charles, MO) and the
Luminex 100 system (Luminex, Austin, TX). Serum levels of MCP-1 and adi-
ponectin were measured with the Milliplex MAP mouse single-plex kit and the
TABLE 1
Primers for gene expression analysis by quantitative RT-PCR
Gene
GeneBank
Accession Number Forward (59–39) Reverse (59–39)
Product
length, bp
Mouse
Adiponectin AF304466 GGAACTTGTGCAGGTTGGAT TCCTGTCATTCCAACATCTCC 162
MCP-1 NM_011333 CGGAACCAAATGAGATCAGAA TGTGGAAAAGGTAGTGGATGC 126
GAPDH BC083149 GGGTGTGAACCACGAGAAATA AGTTGTCATGGATGACCTTGG 104
TNF-a NM_013693 CCAGTCTGTGTCCTTCTA ATCTTGTGTTTCTGAGTAGTT 93
XOR NM_011723 TATGACCGCCTTCAGAAC TATGCCTTCCACAGTTGT 102
b-Actin NM_007393 GAGAGGTATCCTGACCCTGAAGTA TGTTGAAGGTCTCAAACATGATCT 203
Human
Adiponectin NM_004797 AAGGAGATCCAGGTCTTATTG CCCACACTGAATGCTGAG 151
MCP-1 NM_002982 TGTGCCTGCTGCTCATAG CTTGCTGCTGGTGATTCTTC 150
XOR NM_000379 TGGTGGATGCTGTGGAGGAGATG AAGATGGCGAGAGGCTGACTGAG 86
b-Actin NM_001101 CGTGCGTGACATTAAGGAGA AGGAAGGAAGGCTGGAAGAG 177
bp, base pairs.
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spondingly using the Luminex 100 system.
Uric acid and thiobarbituric acid reactive substance assays. Uric acid was
measured by an enzymatic assay with urate oxidase (Diagnostic Chemicals
Limited, Oxford, CT). Thiobarbituric acid reactive substances were measured
with the assay from Cayman Chemical (Ann Arbor, MI).
Statistics. At least three independent experiments were performed in the case
of in vitro studies, and/or 6–10 animals per group were used for the in vivo
studies. Each experiment was performed in triplicate. Data were analyzed by
one-way ANOVA followed by Fisher least signiﬁcant test, unpaired Student
t test, or Mann-Whitney U test, with a value of P , 0.05 considered to represent
a signiﬁcant difference. Comparisons between two values were performed by
t test or U test. ANOVA was used to test differences among several means.
RESULTS
Effect of uric acid on mRNA expression for MCP-1
and adiponectin: dose-response and time course
experiments. To test the effects of uric acid on the adi-
pokine production in vitro, we used differentiated mouse
3T3-L1 adipocytes and human primary subcutaneous adi-
pocytes. When differentiated mouse adipocytes were in-
cubated in the presence of 5 or 15 mg/dL uric acid for 3
days, we observed a signiﬁcant dose-dependent increase
in the mRNA abundance for MCP-1 (Fig. 1A). Even the
lower dose of 5 mg/dL was signiﬁcant (P , 0.05, U test). A
time course experiment showed that 15 mg/dL uric acid
induced an increase in MCP-1 mRNA at day 3, continued to
increase to day 7, and plateaued between days 7 and 14
(Fig. 1B). The mRNA expression for adiponectin, which
was induced by in vitro adipocyte differentiation, was
lowered by both 5 mg/dL and 15 mg/dL of uric acid (Fig.
1C). In time course studies, uric acid also induced a grad-
ual decrease in the adiponectin mRNA in adipocytes
starting from day 3 to day 14 (Fig. 1D). Uric acid produced
a similar effect in human primary subcutaneous adipo-
cytes. Treatment with uric acid at a concentration of 15
mg/dL for 7 days induced a dramatic increase in mRNA
level for MCP-1 and a decrease in the mRNA abundance
for adiponectin (Supplementary Fig. 1A and B). A con-
centration of 7.5 mg/dL, which is a urate concentration
typical for mild hyperuricemia in modern humans (43), did
not produce statistically signiﬁcant effects in this experi-
ment (Supplementary Fig. 1).
Urate-induced activation of MCP-1 production in
mouse adipocytes is prevented by antioxidants and
rosiglitazone. We showed previously (15) that uric acid
induced NOX-dependent reactive oxygen species (ROS)
production in 3T3-L1 adipocytes, which triggered redox-
dependent activation of the proinﬂammatory signaling by
protein kinase p38. Therefore, we tested the hypothesis
that production of proinﬂammatory factors in adipocytes
FIG. 1. Effect of uric acid on the mRNA expression for MCP-1 and adiponectin in 3T3-L1 adipocytes: time course and dose response. Differentiated
3T3-L1 adipocytes were treated with different concentrations of uric acid for varying periods of time. Relative mRNA expression for the MCP-1 (A
and B) and adiponectin (C and D) in the dose response (A and C) and time course (B and D) for the effects of uric acid are shown. The values are
mean 6 SEM for 3–5 independent experiments performed at least in duplicate. *P < 0.05 (nonparametric Mann-Whitney U test) in comparison
with untreated differentiated adipocytes. d, days; CTRL, control; undif., undifferentiated.
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activity is required for this effect. 3T3-L1 adipocytes were
treated with uric acid for 7 days with or without Mn(II)
tetrakis(1-methyl-4-pyridyl)porphyrin (MnTMPyP), a su-
peroxide scavenger, or apocynin, an inhibitor of NADPH
oxidase, and the MCP-1 and adiponectin mRNA and pro-
tein were determined. Uric acid induced a highly signiﬁ-
cant increase in MCP-1 mRNA in cells and protein
concentration in the conditioned medium (Fig. 2A and B)
while the presence of MnTMPyP or apocynin in the me-
dium completely prevented these effects (Fig. 2A and B).
These data suggest that urate-induced activation of the
MCP-1 expression and secretion in adipocytes is mediated
by the superoxide-dependent ROS, likely generated by
NADPH oxidase. Moreover, urate-induced MCP-1 expression
was abrogated by rosiglitazone, a PPAR-g agonist (Fig. 2C
and D), suggesting that activation of PPAR-g prevents the
effect of urate.
Urate-induced decrease in the production of adiponectin
in mouse adipocytes is prevented by rosiglitazone but
not antioxidants. Treatment of adipocytes with 15 mg/dL
uric acid for 7 days induced a dramatic fall in the adipo-
nectin mRNA level, which was accompanied by moderate
but signiﬁcant decrease in the adiponectin concentration
in the incubation medium (Fig. 3A and B). In contrast to
MCP-1, the effect of uric acid on adiponectin production
was not prevented by either MnTMPyP or apocynin (Fig.
3A and B), while rosiglitazone restored adiponectin mRNA
in cells and adiponectin levels in conditioned media to
control levels (Fig. 3C and D). These experiments suggest
that uric acid–induced inhibition of adiponectin pro-
duction is not mediated by redox-dependent signaling but
rather by a mechanism involving PPAR-g.
Effect of uric acid on mRNA expression for XOR.
PPAR-g activation by rosiglitazone prevented the effects of
uric acid in our experiments. On the other hand, XOR, an
FIG. 2. Effect of the superoxide scavenger MnTMPyP and inhibitor of NADPH oxidase apocynin on the uric acid–induced increase in the mRNA
expression and protein release for MCP-1 in 3T3-L1 adipocytes. 3T3-L1 adipocytes were incubated in the presence of 15 mg/dL uric acid with or
without MnTMPyP (25 mmol/L, 30-min preincubation), apocynin (200 mmol/L), or rosiglitazone (10 mmol/L) for 7 days. Medium was changed once
during this period with the fresh aliquot containing the same additives and stored at 280°C to pool with the medium collected at the end of the
treatment. Total mRNA was isolated from the monolayer while media were used for measuring concentration of adipokines. The effect of uric acid
in the presence or absence of antioxidants is shown in A for the relative expression of the mRNA for MCP-1 and in B for the concentration of MCP-
1 in the pooled conditioned medium. The effect of rosiglitazone on the urate-stimulated MCP-1 production is shown in C (relative mRNA ex-
pression) and in D for the released protein. The values are mean 6 SEM for three independent experiments performed in triplicate. *P < 0.05 and
**P < 0.01 (nonparametric Mann-Whitney U test) in comparison with untreated adipocytes. &P < 0.05 (nonparametric Mann-Whitney U test) for
the effect of an antioxidant/rosiglitazone. CTRL, control; Rosi, rosiglitazone; UA, uric acid.
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tor of PPAR-g activity (38). Therefore, we hypothesized
that uric acid could induce downregulation of PPAR-g by
affecting XOR via negative feedback mechanism. We
tested an expression of the XOR mRNA in mouse and
human adipocytes treated with uric acid for 7 days and
found that uric acid induced a signiﬁcant decrease in the
XOR mRNA abundance in both cell types (Supplementary
Fig. 2A and B).
Effect of lowering serum uric acid in mice with
metabolic syndrome. We analyzed several animal models
of obesity and metabolic syndrome or type 2 diabetes in-
cluding Zucker diabetic fatty rats, ZSF1 rats, and the
Pound mouse as well as corresponding lean control ani-
mals of the same age to compare the blood levels of uric
acid in obese and lean animals. As shown in Fig. 4A, for
each analyzed model, the level of uric acid in 8–week-old
obese animals was substantially higher than in the corre-
sponding lean animals. The greatest ratio between the
level of uric acid in the lean control and obese animals
was found in the Pound mice (Fig. 4A) .T h e s em i c eh a v e
metabolic syndrome but do not develop type 2 diabetes
(39) and showed hyperuricemia compared with their lit-
termates (Fig. 4A). Therefore, this model was selected for
further experiments. To lower blood levels of uric acid,
both lean and obese mice were treated with or without
allopurinol for 8 weeks. Obese animals were hyper-
uricemic from the beginning of the study, and hyperuri-
cemia progressed to even higher levels of uric acid during
the course of the experiment (Fig. 4B). The correlation
between the body weight and the level of uric acid in the
Pound mouse is highly signiﬁcant (R =0 . 8 6 0 ,N =3 3 ,P ,
0.001). Serum uric acid substantially decreased in obese
and lean animals after 2 weeks of treatments and
remained low to the end of the study (Fig. 4B). The body
weight gain was not affected by treatments with allo-
purinol in either obese (Fig. 4C)o rl e a na n i m a l s( n o t
shown).
FIG. 3. Effect of the superoxide scavenger MnTMPyP and inhibitor of NADPH oxidase apocynin on the uric acid–induced decrease in the mRNA
expression and protein release for adiponectin in 3T3-L1 adipocytes. The experimental conditions were as described in Fig. 2. The effect of uric
acid in the presence or absence of antioxidants is shown in A for the relative expression of the mRNA for adiponectin and in B for the concen-
tration of adiponectin in the pooled conditioned medium. The effect of rosiglitazone on the urate-stimulated adiponectin production is shown in C
(relative mRNA expression) and D for the released protein. The values are mean 6 SEM for three independent experiments performed in trip-
licate. *P < 0.05 (nonparametric Mann-Whitney U test) in comparison with untreated adipocytes. &P < 0.05 (nonparametric Mann-Whitney U test)
for the effect of an antioxidant/rosiglitazone. CTRL, control; Rosi, rosiglitazone; UA, uric acid.
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the adipose tissue of obese animals compared with lean
control animals whereas adiponectin mRNA expression
was about 20-fold lower than that observed in lean animals
(Fig. 5A and C). Serum concentrations of MCP-1 and adi-
ponectin protein changed correspondingly (Fig. 5B and D).
Lowering uric acid with allopurinol reduced the MCP-1
mRNA expression and serum levels in the Pound mice by
.50% while inducing a threefold increase in adiponectin
mRNA level with an increase in the level of the circulating
adiponectin. Thus, hyperuricemia in the obese mice with
metabolic syndrome might be partially responsible for the
proinﬂammatory generation of MCP-1 by adipose. In ad-
dition, elevated levels of uric acid might contribute to the
decrease in adiponectin. Because lowering urate blood
levels with allopurinol improved the balance of the pro-
duction of MCP-1 and adiponectin, hyperuricemia might
contribute to the proinﬂammatory endocrine imbalance in
the adipose tissue.
In order to check whether lowering uric acid reduced
signs of inﬂammation in the adipose tissue in addition to
MCP-1 production, we examined the visceral adipose tis-
sue for the presence of macrophages, a key step in
proinﬂammatory changes in obesity (42,44). The number
of the F4/80-stained macrophages was negligent in lean
mice and increased dramatically in obese mice (Fig. 6A, B,
and D) while it signiﬁcantly decreased in obese mice
treated with allopurinol (Fig. 6C and D). Because expres-
sion of the proinﬂammatory cytokine TNF-a in the adipose
tissue is elevated in obesity and it is macrophage-speciﬁc
(44), we measured the abundance of mRNA for TNF-a in
the adipose tissue. As expected, the TNF-a mRNA was
induced dramatically in the Pound mice while allopurinol
treatment reduced it (Fig. 6E), consistent with changes in
macrophage inﬁltration and changes in the MCP-1 pro-
duction. Obesity is associated also with oxidative stress in
the adipose tissue (45). Proinﬂammatory effects of uric
acid in our experiments were also redox-dependent. We
assessed the effect of lowering uric acid on the level of
oxidative stress by measuring malondialdehide (MDA),
a product of lipid peroxidation. MDA levels in the visceral
adipose tissue and serum of obese mice was increased
while allopurinol treatment substantially reduced it (Fig.
6F and G).
Effect of lowering uric acid in Pound mice on signs of
metabolic syndrome. The proinﬂammatory endocrine
imbalance and low-grade inﬂammation in the visceral ad-
ipose tissue is an underlying mechanism in the insulin
FIG. 4. Hyperuricemia in the mouse model of metabolic syndrome. A: Blood levels of uric acid in several models of obesity, metabolic syndrome, and
diabetes: the Pound mouse (obesity, metabolic syndrome, described in the RESEARCH DESIGN AND METHODS section) vs. lean (+/?) control; ZDF fa/fa rats
(obesity, type 2 diabetes) vs. lean (+/?) control; ZSF obese vs. lean (+/?) control. B: Changes in the blood levels of uric acid in the lean and obese
Pound mice during the course of the experiment and the effect of treatments with allopurinol. Allopurinol did not affect body weight in the lean
animals (not shown). C: Time course for the body weight for lean and obese Pound mice treated with allopurinol. The values are mean 6 SEM (N =
8–10, performed in duplicate). **P < 0.01 and ***P < 0.001 (U test) for the effect of obesity. ###P < 0.001 (U test) for the effect of allopurinol.
Allop, allopurinol; CTRL, control.
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with metabolic syndrome (18,19,29,30). To test whether
lowering uric acid can improve signs of metabolic syn-
drome, we performed insulin tolerance tests and measured
blood pressure in obese mice treated with allopurinol. As
expected, obese mice had dramatically reduced insulin
sensitivity (Fig. 7A) and elevated MAP in comparison with
lean mice (Fig. 7B and C). Lowering uric acid signiﬁcantly
improved both parameters (Fig. 7A–C).
DISCUSSION
We found that uric acid can increase expression and re-
lease of MCP-1 and reduce production of adiponectin in
cultured adipocytes. We further showed that an increase in
MCP-1 with a reduction in adiponectin occurs in both ad-
ipose tissue and serum of the obese, hyperuricemic Pound
mice, and that lowering uric acid can attenuate these
changes. Obesity is associated with an increase in MCP-1
production (27,28) and a decrease in the adiponectin
production (19,46) in the adipose tissue. These changes
contribute substantially to the obesity-related low-grade
inﬂammation and metabolic syndrome, including insulin
resistance and hypertension (17,25). A dramatic increase
in macrophage inﬁltration with expression of the proin-
ﬂammatory cytokine TNF-a was observed in visceral adi-
pose tissue in obese mice and is consistent with reported
results (42,44). Importantly, lowering uric acid caused
a reduction in macrophage inﬁltration and TNF-a expres-
sion as well as improved insulin sensitivity and blood
pressure. This study may provide a mechanism linking
hyperuricemia, obesity, and metabolic syndrome that has
been shown previously in clinical studies (4,5,12). The
observation that lowering uric acid improved but did not
reverse the changes in MCP-1 and adiponectin, inﬂam-
mation, and insulin resistance in the Pound mouse is
FIG. 5. The effect of lowering uric acid with allopurinol on the MCP-1 and adiponectin production in the adipose tissue of the obese Pound mice.
Obese Pound mice and lean (+/?) control mice were treated with allopurinol for 8 weeks as described in the RESEARCH DESIGN AND METHODS section.
mRNA abundance (A and C) as well as blood levels (B and D) for MCP-1 (A and B) and adiponectin (C and D) were measured at the end of the
experiment. The values are mean 6 SEM (N =8 –10, performed in duplicate). *P < 0.05 and ***P < 0.001 (U test), correspondingly, for the effect of
obesity. &P < 0.05 for the effect of allopurinol.
HYPERURICEMIA AND ADIPOSE TISSUE
1264 DIABETES, VOL. 60, APRIL 2011 diabetes.diabetesjournals.orgFIG. 6. The effect of lowering uric acid levels on the macrophage inﬁltration, TNF-a expression, and oxidative stress in the adipose tissue of the
obese Pound mice. Samples of the adipose tissue from lean (A), obese (Pound) (B), and obese mice treated with allopurinol for 8 weeks (C) were
stained with F4/80 antibody and counterstained with hematoxylin. Because diaminobenzidine was used as a chromogen, macrophages (F4/80-
positive cells) are stained in brown as indicated with arrowheads (see also magniﬁed rectangular region). D: The percentage of F4/80-positive
macrophages within the adipose tissue is greatly induced by obesity and reduced by allopurinol treatment. Allopurinol did not affect macrophage
staining in lean mice (not shown). Counting positive and negative cells were performed in a blind fashion at least in three ﬁelds per animal.
E: Effect of allopurinol treatment on the relative expression of mRNA for TNF-a in the visceral adipose tissue of the obese (Pound) mice. In
addition, the level of the oxidative stress in the serum (F) and in the visceral fat (G) in these mice was assessed by measuring the product of lipid
peroxidation MDA using thiobarbituric acid reactive substance assay. The values are mean 6 SEM (N =5 –6, performed in triplicate). **P < 0.01
and ***P < 0.001 (U test), correspondingly, for the effect of obesity. &P < 0.05 for the effect of allopurinol. WAT, white adipose tissue. (A high-
quality digital representation of this ﬁgure is available in the online issue.)
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the sole causal factor—in driving these changes.
We observed an increase in serum uric acid in the Pound
mice and other animal models of obesity in comparison
with the corresponding lean controls. This observation is
in agreement with published data (38,47). Hyperuricemia
progressed as animals gained weight, and the level of uric
acid correlated with the body weight. As these mice are
obese and insulin-resistant because of the mutation in the
leptin receptor (39), hyperuricemia cannot be considered
as a causal factor of obesity in this case. However, an
increase in uric acid contributed to the low-grade in-
ﬂammation and metabolic syndrome via its direct effect on
the production of MCP-1 and adiponectin in the adipose
tissue.
In mouse 3T3-L1 adipocytes and human primary adipo-
cytes, uric acid can induce a direct dose-dependent in-
crease in the production of MCP-1 and a decrease in the
production of adiponectin at the level of the mRNA ex-
pression and protein release. For mice, cells responded to
uric acid beginning at concentrations of 5 mg/dL, which is
similar to the levels of uric acid in the obese Pound mice.
In the case of human adipocytes, cells responded to 7.5–15
mg/dL uric acid, which encompass the range observed in
subjects with asymptomatic hyperuricemia to severe gout (3).
The ability of soluble uric acid to induce MCP-1 ex-
pression was ﬁrst demonstrated in rat vascular smooth
muscle cells (31). The effect of uric acid was mediated by
MAP kinases ERK1/2 and p38 and nuclear factor-kBi n
a redox-dependent fashion (31). In our previous work with
3T3-L1 adipocytes (15), we showed that uric acid induced
ROS production via activation of NADPH oxidase followed
by phosphorylation of p38. The urate-induced increase in
the MCP-1 expression in adipocytes was downregulated by
a superoxide scavenger and a NOX inhibitor. Collectively,
these data suggest that uric acid induced MCP-1 pro-
duction in adipocytes via the redox-dependent signaling
initiated by NOX activation. Furukawa et al. (45) reported
that obesity was associated with oxidative stress in adi-
pose tissue, which, in turn, caused an overexpression of
a variety of proinﬂammatory cytokines including MCP-1.
We observed an increase in oxidative stress in our mouse
model of obesity by measuring MDA in the adipose tissue
and serum. This was reduced by allopurinol, suggesting
that hyperuricemia induced by obesity is another mecha-
nism triggering oxidative stress followed by induction of
the MCP-1 expression and inﬂammation in the adipose
tissue.
The uric acid–induced increase in the MCP-1 production
observed in adipocytes was prevented not only by anti-
oxidants but also by activation of PPAR-g with rosi-
glitazone. An activation of PPAR-g i sk n o w nt ob l o c k
the proinﬂammatory effects of TNF-a in adipocytes by
affecting the proinﬂammatory branch of the nuclear
FIG. 7. Lowering uric acid levels in obese (Pound) mice improves signs of metabolic syndrome (insulin resistance, hypertension). A: To assess level
of insulin sensitivity, the insulin tolerance test was used. Insulin (1 unit/kg) was injected, and blood level was measured at 0, 15, 30, 60, 90, and 120
min after injection. Sensitivity to insulin was normal in lean mice but dramatically reduced in obese mice, which was partially improved by
treatment with allopurinol. B: Obesity induced increase in the MAP in mice, which was attenuated by allopurinol treatment. C: Representative
recordings of blood pressure averaged in B. The values are mean 6 SEM (N =5 –6, performed in triplicate). **P < 0.01 and ***P < 0.001 (U test),
correspondingly, for the effect of obesity. ##P < 0.01 for the effect of allopurinol. Allo, allopurinol; CTRL, control. (A high-quality color repre-
sentation of this ﬁgure is available in the online issue.)
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thought to be a crucial upstream regulator of PPAR-g ac-
tivity (38). Treating adipocytes with exogenous uric acid
reduced expression of XOR, which could be a cause of
downregulated anti-inﬂammatory activity of PPAR-g and
facilitated redox-dependent MCP-1 production.
The mechanism of downregulation of the adiponectin
production in obesity is not completely understood but
appears to involve proinﬂammatory pathways (48,49),
oxidative stress (45), and a deﬁciency in the PPAR-g ac-
tivity (48,50). The uric acid–induced decrease in adipo-
nectin expression and secretion in our experiments was
FIG. 8. Model for the effect of hyperuricemia on the endocrine balance in adipocytes. This model summarizes the results of the current and the
previous (15) studies. Uric acid can enter adipocytes through a uric acid–speciﬁc transporter. We identiﬁed that adipocytes express at least one
uric acid transporter, URAT1. Activation of NOX by uric acid occurs via unknown mechanism, and it was localized on the plasma membrane as well
as on intracellular membranes. ROS generated from superoxide produced by NOX is followed by ROS-dependent activation of the proinﬂammatory
signaling via p38. An activation of this mechanism in response to uric acid is followed by an increase in the production of MCP-1 and a decrease in
the production of adiponectin. In addition, uric acid entering the adipocyte may downregulate expression of XOR, which (xanthine dehydrogenase
but not xanthine oxidase) is known as a crucial upstream regulator of activity of PPAR-g, a master-regulator of adipogenesis, expression of
adiponectin, and an anti-inﬂammatory factor in adipocytes (38). Upregulation of MCP-1 in response to uric acid can be prevented by a superoxide
scavenger or by inhibiting NOX. PPAR-g activation can prevent both effects of uric acid. The effect of hyperuricemia might be partially responsible
for the low-grade inﬂammation and insulin resistance in the adipose tissue and for increased risk of cardiovascular disease induced by obesity.
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ing an involvement of the same kind of proinﬂammatory
mechanism that was responsible for the induction of
MCP-1. On the other hand, antioxidants could not im-
prove adiponectin production affected by uric acid. We
can suggest therefore that the deﬁciency of PPAR-g but
not oxidative stress was a primary trigger of this down-
regulation.
Because rosiglitazone prevented the uric acid–induced
induction of MCP-1 and downregulation of adiponectin,
these effects of uric acid might depend on PPAR-g. XOR-
dependent regulation of the adipocyte differentiation via
control of PPAR-g activity is known to be a ﬁnely or-
chestrated mechanism, which could be affected by ma-
nipulating the expression of XOR (38). Our data suggest
that elevated concentrations of uric acid may reduce ex-
pression of XOR and attenuate PPAR-g–dependent endo-
crine regulation in adipocytes.
In summary, uric acid can affect adipocytes directly
by inducing effects resembling those observed in obesity:
upregulation of proinﬂammatory factors and downregula-
tion of the production of the insulin sensitizer and anti-
inﬂammatory factor adiponectin via redox-dependent
mechanisms, which can be prevented by an agonist of
PPAR-g (Fig. 8). In the mouse model of the metabolic
syndrome, we observed hyperuricemia, which progressed
with an increase in body weight. Lowering uric acid by
inhibiting xanthine oxidoreductase in obese mice with the
metabolic syndrome could improve the proinﬂammatory
endocrine imbalance in the adipose tissue by lowering
production of MCP-1 and increasing production of adipo-
nectin.
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